Centers for Disease Control and Prevention, Division of Viral Hepatitis. Viral hepatitis surveillance, United States. Atlanta, Georgia: CDC Division of Viral Hepatitis; 2016.
Campbell CA, Canary L, Smith N, et al. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs—United States, 2015– 2016. MMWR Morb Mortal Wkly Rep. 2017:66(18):465-469.
Chhatwal J, Chen Q, Bethea ED, et al. The impact of direct-acting anti‐virals on the hepatitis C care cascade: Identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019;50(1):66-74. doi:10.1111/apt.15291.
AASLD/IDSA HCV guidance recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. May 2018. Accessed March 2019.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Chronic hepatitis C virus infection: Developing direct-acting antiviral drugs for treatment, guidance for industry. Silver Spring, Maryland: FDA CDER; November 2017.
Centers for Disease Control and Prevention. Hepatitis C Questions and Answers for Health Professionals. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1. Reviewed April, 2019. Accessed June 19, 2019.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.
Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-521.
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47(RR-19):1-54.